MiR-378 Controls Cardiac Hypertrophy by Combined Repression of MAP Kinase Pathway Factors.
Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S
Circulation. 2013, 127(21), 2097-106